Related Experiment Videos
Statin therapy in the heart and estrogen/progestin replacement study
1Division of Cardiology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Minerva Ginecologica
|October 29, 2003
Summary
Statins benefit postmenopausal women with coronary heart disease (CHD) for secondary prevention. They may also reduce cardiovascular risks associated with hormone replacement therapy (HRT).
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Women's Health
Background:
- Limited data exists for secondary prevention in postmenopausal women with coronary heart disease (CHD).
- Conflicting clinical trial results and potential interactions between statins and hormone replacement therapy (HRT) complicate treatment decisions.
Purpose of the Study:
- To evaluate the efficacy of statins in postmenopausal women with CHD.
- To assess the interaction between statins and HRT in cardiovascular outcomes.
Main Methods:
- A post hoc analysis of the HERS trial was conducted.
- Patients were stratified based on baseline statin use (statin vs. no statin).
- Outcomes included myocardial infarction, CHD death, all-cause mortality, and venous thromboembolism (VTE).
Main Results:
- Baseline statin use was associated with significantly lower rates of myocardial infarction or fatal CHD (RH=0.78) and all-cause mortality (RH=0.74).
- Statin therapy reduced the incidence of VTE in both HRT and placebo groups.
- The negative effect of HRT on the primary outcome was attenuated in baseline statin users.
Conclusions:
- Findings support the use of statins for secondary prevention in postmenopausal women with cardiovascular disease.
- Statins may mitigate the increased cardiovascular risk associated with HRT.